Navigation Links
Perdue Kidd & Vickery Files Lawsuit Against Abbott Laboratories for Inadequate Leukemia and Cancer Warning

DALLAS, July 29, 2011 /PRNewswire/ -- Humira defect lawyers filed a lawsuit against Abbott Laboratories in Texas state court claiming Abbott's blockbuster drug, Humira, caused a life-threatening disease, leukemia.

"Eleven year-old Bo Anderson was prescribed Humira for a skin condition, psoriasis.  After taking the drug for approximately ten months, Bo's parents noticed unusual bruising covering his body while on a family vacation," says drug defect attorney Andy Vickery.

"Bo immediately underwent various tests and was diagnosed with T cell acute lymphoblastic leukemia; a dangerous side effect Abbott Laboratories knew could affect Humira users but failed to warn them about."  

Vickery says because of the Humira-induced leukemia, Bo now must continue to undergo intense treatment that could potentially cause long-term and serious side effects, and could possibly develop secondary cancers as he matures.

Prior to the launch of Humira in 2003, other similar drugs had been linked to lymphoma and other forms of cancer, and clinical trial data suggested that there was a very significant epidemiological "signal" about the risk.  Once Humira was launched, many adverse event reports were submitted regarding cancers, however Abbott did nothing to warn about this.  Bo was diagnosed with Leukemia on January 8, 2009, over seven months after the FDA said that physicians and patients should be warned about this side effect, and nearly ten months before a Black Box warning was finally issued regarding Humira-induced leukemia in pediatric and adolescent patients.

Humira (Adalimumab) is a class of biologic drugs known as TNF (Tumor Necrosis Factor) blockers. It works by blocking naturally occurring proteins that cause inflammation.  However, research has shown that taking drugs like Humira can compromise the immune system and can have a devastating and even deadly effect resulting in serious infections, cancer, allergic reactions, Hepatitis B virus reactivation, nervous system problems, heart failure, blood issues and certain immune reactions. Humira is used for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, crohn's disease, and plaque psoriasis. With 2010 sales of $6.5 billion, Humira is Abbott's flagship drug.

Perdue Kidd & Vickery is a national law firm of Board Certified Personal Injury Trial Lawyers.  The law practice is based in Houston, TX.   Further information is available at View an educational video about Humira fungal infections.

SOURCE Perdue Kidd & Vickery
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
2. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
3. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
4. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
5. Robbins & Myers Announces Regular Quarterly Cash Dividend
6. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
7. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
8. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
9. Robbins & Myers Announces Fourth Quarter and Full Year 2009 Results
10. Dynatronics Appoints Douglas Sampson as Vice President of Production and Research & Development
11. Frost & Sullivan Identifies Focus on Quality Management and Adoption of a Full-service Model as Keys to the Growth of the European CRO Market
Post Your Comments:
(Date:11/25/2015)... WILMINGTON, N.C. , Nov. 25, 2015 /PRNewswire/ ... announces the planned investment of at least $15.8 ... in Wilmington, NC . The ... services capacity to meet the growing demands of ... Wilmington site expansion will provide up ...
(Date:11/25/2015)... Allergan plc (NYSE: AGN ) today announced that it ... State Attorney General,s Office to end the litigation ... with the Attorney General over the decision of Forest Laboratories, ... the now generic version of memantine immediate release tablets.  Under ... its counterclaims against New York , and ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
(Date:11/26/2015)... (PRWEB) , ... November 26, ... ... online platform for mental health and wellness consultation, has collaborated with Women’s ... holistically address their reader’s queries on topics on mental and emotional well-being ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Finnleo, a ... Christmas Eve on several models of traditional and far-infrared saunas. , For ... Spruce is the most traditional Finnish sauna wood, and Finnleo uses only European Grade ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 10, 2015, Bohrer ... Court of Connecticut on behalf of a home health care worker who provided companionship ... former home health care workers employed by Humana, Inc., Humana at Home, Inc., and ...
(Date:11/25/2015)... ... , ... On November 25, 2015, officials of Narconon Arrowhead , the ... of a new cutting edge recovery program that has been 50 years in the ... alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative behaviors ...
Breaking Medicine News(10 mins):